SAN FRANCISCO – LifeAssist Technologies has been selected by the Centre for Aging + Brain Health Innovation to participate in the Industry Innovation Partnership Program.
I2P2 seeks to connect companies who have innovative aging and brain health products/services that are at an advanced stage of development with health care institutions who are seeking solutions to challenging issues in aging and brain health.
Through the program, LifeAssist will partner with Toronto Central Local Health Integration Network and Baycrest Health Sciences to evaluate and validate medication adherence, efficiency, resource utilization and overall senior care participant’s satisfaction and engagement in health management.
The focus of the trial is on enhancing medication and related compliance for homecare clients and long-term residents.
“Our focus is assisting people during health care transitions and the care coordination that promotes independence,” said Tim Pauley, manager of research and knowledge mobilization, Toronto Central Local Health Integration Network, in a statement. “Our clinical trial with LifeAssist’s medication adherence technology and in-home device is a great opportunity to enhance medication compliance in a home setting.”
LifeAssist competed against companies around the world for the opportunity to participate in the program, which will provide further validation of LifeAssist’s Circura + Rosie medication management and care coordination platform/device.
“We are very happy to be an I2P2 partner with LifeAssist,” says Dr. Anna Ballon, Executive Director, Residential Living and Community Programs, Baycrest. “This I2P2 project will enhance care and connectivity across senior-friendly communities and specialized programs,” said Dr. Anna Ballon, executive director of residential living and community programs at Baycrest Health Sciences, in a statement.